| Literature DB >> 35891266 |
Mikiko Tokiya1, Megumi Hara2, Akiko Matsumoto1, Mohammad Said Ashenagar1, Takashi Nakano3, Yoshio Hirota4.
Abstract
The Japanese government approved COVID-19 vaccine booster doses in November 2021. However, intentions and readiness for booster vaccines among the general population were unknown. This survey measured the intentions for COVID-19 booster vaccination. Among 6172 participants (53.2% female), 4832 (78.3%) accepted booster doses; 415 (6.7%) hesitated. Vaccination intention was associated with higher age, marital status, having children, underlying diseases, and social norms. To evaluate the readiness for vaccination, the seven component (7C) vaccination readiness scale was employed, comprising "Confidence", "Complacency", "Constraints", "Calculation", "Collective responsibility", "Compliance", and "Conspiracy". Participants with acceptance showed significantly higher 7C scores (p < 0.001) than those who hesitated or were unsure. Multivariable logistic regression analysis revealed that the "social norms" predictor was the strongest predictor of acceptance (adjusted odds ratio (AOR) 4.02, 95% confidence interval (CI): 3.64-4.45). "Constraints" (AOR: 2.27, 95% CI: 2.11-2.45) and "complacency" (AOR: 2.18, 95% CI: 2.03-2.34) were also strongly associated with acceptance, but "compliance" (AOR: 1.24, 95% CI: 1.18-1.31) and "conspiracy" (AOR: 1.42, 95% CI: 1.33-1.52) were weakly associated. The "7C vaccination readiness scale" is useful for measuring vaccine acceptance in the Japanese population. However, "social norms" might be more suitable than "compliance" and "conspiracy" for measuring vaccine acceptance in Japan.Entities:
Keywords: 7C; epidemiology; intention; readiness; scale; social norms; survey; vaccine
Year: 2022 PMID: 35891266 PMCID: PMC9323594 DOI: 10.3390/vaccines10071102
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Participant responses to “I would like to get the third vaccination (booster) when I get the information”.
|
| (%) | |
|---|---|---|
| Strongly agree | 2317 | 37.5 |
| Agree | 2515 | 40.8 |
| Neither or not | 925 | 15.0 |
| Disagree | 289 | 4.7 |
| Strongly disagree | 126 | 2.0 |
Characteristics of participants with the intention to receive the booster dose of the COVID-19 vaccine.
|
| Acceptance | Not Sure | Hesitancy | |||
|---|---|---|---|---|---|---|
| Sex | Male | 2890 | 2319 (80.2) | 386 (13.4) | 185 (6.4) | 0.001 |
| Female | 3282 | 2513 (76.6) | 539 (16.4) | 230 (7.0) | ||
| Age | (Mean: years old) | 52.5 | 43.2 | 42.6 | <0.001 | |
| 20–29 | 791 | 521 (65.9) | 180 (22.8) | 90 (11.4) | <0.001 | |
| 30–39 | 1054 | 688 (65.3) | 254 (24.1) | 112 (10.6) | ||
| 40–49 | 1133 | 828 (73.1) | 211 (18.6) | 94 (8.3) | ||
| 50–59 | 1151 | 957 (83.2) | 137 (11.9) | 57 (5.0) | ||
| 60–69 | 1018 | 903 (88.7) | 81 (8.0) | 34 (3.3) | ||
| 70–79 | 1025 | 935 (91.2) | 62 (6.1) | 28 (2.7) | ||
| Area | Hokkaido | 291 | 217 (74.6) | 56 (19.2) | 18 (6.2) | 0.193 |
| Tohoku | 336 | 266 (79.2) | 40 (11.9) | 30 (8.9) | ||
| Kanto | 2373 | 1890 (79.7) | 334 (14.1) | 149 (6.3) | ||
| Chubu | 994 | 755 (76.0) | 164 (16.5) | 75 (7.6) | ||
| Kinki | 1211 | 945 (78.0) | 182 (15.0) | 84 (6.9) | ||
| Chugoku | 307 | 232 (75.6) | 56 (18.2) | 19 (6.2) | ||
| Shikoku | 145 | 117 (80.7) | 20 (13.8) | 8 (5.5) | ||
| Kyusyu | 515 | 410 (79.6) | 73 (14.2) | 32 (6.2) | ||
| Married | No | 2275 | 1680 (73.9) | 402 (17.7) | 193 (8.5) | <0.001 |
| Yes | 3897 | 3152 (80.9) | 523 (13.4) | 222 (5.7) | ||
| Child | No | 2507 | 1822 (72.7) | 470 (18.8) | 215 (8.6) | <0.0001 |
| Yes | 3665 | 3010 (82.1) | 455 (12.4) | 200 (5.5) | ||
| Annual household income | <JPY 4 million | 1654 | 1312 (79.3) | 234 (14.2) | 108 (6.5) | <0.001 |
| ≥JPY 4 million | 3170 | 2539 (80.1) | 440 (13.9) | 191 (6.0) | ||
| Unknown | 1348 | 981 (72.8) | 251 (18.6) | 116 (8.6) | ||
| Educational attainment | High school graduate | 1781 | 1404 (78.8) | 251 (14.1) | 126 (7.1) | 0.389 |
| Above higher education | 4391 | 3428 (78.1) | 674 (15.4) | 289 (6.6) | ||
| Body mass index ≥ 25 kg/m2 | No | 5013 | 3885 (77.5) | 773 (15.4) | 355 (7.1) | 0.005 |
| Yes | 1159 | 947 (81.7) | 152 (13.1) | 60 (5.2) | ||
| Underlying disease | No | 3965 | 2956 (74.6) | 698 (17.6) | 311 (7.8) | <0.001 |
| Yes | 2207 | 1876 (85.0) | 227 (10.3) | 104 (4.7) | ||
| Smoking | No | 5225 | 4075 (78.0) | 787 (15.1) | 363 (7.0) | 0.218 |
| Yes | 947 | 757 (79.9) | 138 (14.6) | 52 (5.5) | ||
| SARS-CoV-2 infection status (myself) | No | 6116 | 4790 (78.3) | 916 (15.0) | 410 (6.7) | 0.870 |
| Yes | 56 | 42 (75.0) | 9 (16.1) | 5 (8.9) | ||
| SARS-CoV-2 infection status (family, etc.) | No | 5396 | 4241 (78.6) | 811 (15.0) | 344 (6.4) | 0.016 |
| Yes | 776 | 591 (76.2) | 114 (14.7) | 71 (9.2) | ||
| SARS-CoV-2 infection status (inspection only) | No | 5344 | 4191 (78.4) | 807 (15.1) | 346 (6.5) | 0.127 |
| Yes | 828 | 641 (77.4) | 118 (14.3) | 69 (8.3) | ||
| If most people take a booster dose, I will do too (Social norms) | Strongly disagree | 151 | 67 (44.4) | 4 (2.7) | 80 (53.0) | <0.001 |
| Disagree | 326 | 133 (40.8) | 26 (8.0) | 167 (51.2) | ||
| Neither or not | 1159 | 481 (41.5) | 560 (48.3) | 118 (10.2) | ||
| Agree | 2766 | 2401 (86.8) | 319 (11.5) | 46 (1.7) | ||
| Strongly agree | 1770 | 1750 (98.9) | 16 (0.9) | 4 (0.2) |
p-values were calculated using the 3 × n χ2 test. Mean age was calculated using a one-way analysis of variance. The Bonferroni method defined a significance level of less than 0.001 as 0.05/50 = 0.001. SARS-CoV-2 infection status (family, etc.) refers to family members, friends, and business associates.
Adverse events of previous vaccination by intention to receive the booster dose of the COVID-19 vaccine.
| Adverse Events/Yes | Acceptance | Not Sure | Hesitancy | |
|---|---|---|---|---|
| Lumps at the vaccination site | 870 (18.0) | 155 (16.8) | 58 (14.0) | 0.093 |
| Itching at the vaccination site | 626 (13.0) | 144 (15.6) | 64 (15.4) | 0.052 |
| Pain at the vaccination site | 3210 (66.4) | 632 (68.3) | 275 (66.3) | 0.525 |
| Redness at the vaccination site | 979 (20.3) | 198 (21.4) | 79 (19.0) | 0.577 |
| Swelling of the inoculation site | 1517 (31.4) | 299 (32.3) | 152 (36.6) | 0.086 |
| Fever | 2142 (44.3) | 517 (55.9) | 259 (62.4) | <0.001 |
| Tiredness, fatigue | 2039 (42.2) | 491 (53.1) | 234 (56.4) | <0.001 |
| Headache | 1036 (21.4) | 293 (31.7) | 157 (37.8) | <0.001 |
| Chills | 534 (11.1) | 167 (18.1) | 97 (23.4) | <0.001 |
| Vomiting | 64 (1.3) | 24 (2.6) | 17 (4.1) | <0.001 |
| Diarrhea | 80 (1.7) | 19 (2.1) | 24 (5.8) | <0.001 |
| Muscular pain | 1092 (22.6) | 266 (28.8) | 149 (35.9) | <0.001 |
| Arthralgia | 450 (9.3) | 148 (16.0) | 87 (21.0) | <0.001 |
| Anaphylactic shock | 11 (0.2) | 3 (0.3) | 5 (1.2) | 0.003 |
| None | 457 (9.5) | 76 (8.2) | 30 (7.2) | 0.186 |
* p-values were calculated using the 3 × 2 χ2 test.
Figure 1The 7C scale of vaccination readiness means’ score (age, sex-adjusted) according to the intention to be vaccinated (p-value calculated by Kruskal–Wallis test for “hesitancy”, “not sure”, and “acceptance” scores).
Logistic regression analysis of factors associated with acceptance of the booster dose of vaccination.
| Crude OR | 95% CI | Adjusted * OR | 95% CI | Eta ** | |||
|---|---|---|---|---|---|---|---|
| Sex | 0.81 | 0.71–0.91 | 0.001 | 0.95 | 0.81–1.10 | 0.483 | 0.07 |
| Age | 1.46 | 1.40–1.52 | <0.001 | 1.39 | 1.31–1.47 | <0.001 | |
| Child | 1.73 | 1.53–1.95 | <0.001 | 0.98 | 0.83–1.15 | 0.777 | |
| Annual household income | 1.05 | 0.91–1.22 | 0.526 | 1.27 | 1.08–1.49 | 0.003 | |
| Underlying disease | 1.94 | 1.69–2.22 | <0.001 | 1.30 | 1.10–1.54 | 0.003 | |
| Social norms | 3.98 | 3.66–4.34 | <0.001 | 4.02 | 3.64–4.45 | <0.001 | 0.27 |
| Confidence | 1.80 | 1.71–1.90 | <0.001 | 1.76 | 1.65–1.87 | <0.001 | 0.13 |
| Complacency | 2.34 | 2.20–2.49 | <0.001 | 2.18 | 2.03–2.34 | <0.001 | 0.18 |
| Constraints | 2.41 | 2.26–2.56 | <0.001 | 2.27 | 2.11–2.45 | <0.001 | 0.18 |
| Calculation | 1.12 | 1.07–1.17 | <0.001 | 1.10 | 1.04–1.16 | 0.001 | 0.07 |
| Collective responsibility | 1.83 | 1.73–1.93 | <0.001 | 1.77 | 1.65–1.90 | <0.001 | 0.13 |
| Compliance | 1.25 | 1.19–1.31 | <0.001 | 1.24 | 1.18–1.31 | <0.001 | 0.08 |
| Conspiracy | 1.53 | 1.45–1.62 | <0.001 | 1.42 | 1.33–1.52 | <0.001 | 0.09 |
* Adjusted for sex, age, children, underlying disease status, household income, and adverse events of previous vaccination (fever, tiredness, fatigue, headache, cold, vomiting, diarrhea, muscular pain, arthralgia, and anaphylactic shock). However, sex, age, children, underlying disease status, and household income were adjusted all at once. ** The effect size (eta squared) was calculated using the General Linear Model, adjusted for age, children, underlying disease status, household income, and adverse events of previous vaccination (fever, washed-out feeling, headache, cold, vomiting, diarrhea, muscular pain, arthralgia, anaphylactic shock). OR: odds ratio; CI: confidence interval.